Rtw Investments, LP Macrogenics Inc Transaction History

Rtw Investments, LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	BUY	$19.74 - $28.7 $28.2 Million - $41 Million	1,428,629 Added 56.09%	3,975,554 $83.2 Million
Q2 2021 Aug 13, 2021	BUY	$20.49 - $35.63 $10.9 Million - $19 Million	532,525 Added 26.44%	2,546,925 $68.4 Million
Q1 2021 May 14, 2021	BUY	$18.99 - $33.2 $14.4 Million - $25.2 Million	757,991 Added 60.33%	2,014,400 $64.2 Million
Q4 2020 Feb 16, 2021	BUY	$19.41 - $26.0 $21,545 - $28,860	1,110 Added 0.09%	1,256,409 $28.7 Million
Q3 2020 Nov 16, 2020	BUY	$24.69 - $31.6 $234,135 - $299,662	9,483 Added 0.76%	1,255,299 $31.6 Million
Q2 2020 Aug 14, 2020	BUY	$5.2 - $29.12 $6.48 Million - $36.3 Million	1,245,816 New	1,245,816 $34.8 Million

132

55.4M

215K

238K

Ticker MGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,458,800
Market Cap $209M
Description
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...

Get notified when there are updates to the investment portfolio of Rtw Investments, LP, based on Form 13F filings with the SEC.

Stay updated on Rtw Investments, LP with notifications on news.